Avacta opens first US clinical investigator sites
(Sharecast News) - Life sciences company Avacta has opened its first two clinical investigator sites in the US for a Phase 1 clinical study on its AVA6000 candidate.
Read moreTue, 09th Mar 2021 11:08
(Sharecast News) - Life sciences company Avacta has opened its first two clinical investigator sites in the US for a Phase 1 clinical study on its AVA6000 candidate.
Read more(Sharecast News) - Life sciences company Avacta Group announced that it had dosed the first patient in the fifth cohort of the first-in-human phase one trial of its innovative oncology drug 'AVA6000' on Wednesday.
Read more(Alliance News) - Avacta Group PLC on Wednesday said the first patient has been dosed in the fifth cohort of the first-in-human phase 1 trial of AVA6000, a novel form of doxorubicin designed to improve its safety and therapeutic index.
Read more(Sharecast News) - Life science company Avacta Group announced on Monday that it will present a poster on its novel 'preCISION' medicine, 'AVA3996', at the American Association for Cancer Research (AACR) 2023 annual meeting in Florida on 16 April.
Read more(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:
Read more(Sharecast News) - Life science company Avacta reassured the market on Monday, following the collapse of technology and science-focussed Silicon Valley Bank last week.
Read more(Sharecast News) - Oncology drug and diagnostics developer Avacta Group said in an update on Tuesday that 'AVA6000' was continuing to show a "very favourable" safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase-one clinical trial.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more(Alliance News) - Avacta Group PLC on Tuesday closed its GBP2.0 million open offer of shares, bringing its total fundraise to GBP64.0 million.
Read more(Alliance News) - Avacta Group PLC on Tuesday announced a GBP62.0 million fundraise, which will be partially used to finance its acquisition of Launch Diagnostics Holdings Ltd for up GBP37 million.
Read more(Sharecast News) - Clinical-stage oncology drug company Avacta has conditionally agreed to acquire Launch Diagnostics, it announced on Tuesday, for an upfront cash consideration of £24m on a debt-free, cash-free basis.
Read more(Sharecast News) - Clinical-stage oncology drug developer Avacta reported first-half revenue of £5.5m on Thursday, up from £1.5m year-on-year and from £2.9m for the full 2021 period.
Read more(Alliance News) - Avacta Group PLC on Thursday reported a narrowed interim loss as it multiplied its revenue significantly thanks to a strong performance from its Therapeutics division.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.
Read more(Alliance News) - Avacta Group PLC on Monday said it received approval for its AVA6000 for treatment of soft tissue sarcoma.
Read more